5:14 PM
 | 
May 25, 2010
 |  BC Extra  |  Company News

Avila, Clovis in cancer deal

Avila Therapeutics Inc. (Waltham, Mass) granted Clovis Oncology Inc. (Boulder, Colo.) exclusive, worldwide rights to develop and commercialize its EGFR mutant-selective inhibitor (EMSI) program. The...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >